MARKET

LUNG

LUNG

Pulmonx Corp
NASDAQ
9.27
+0.16
+1.76%
After Hours: 9.27 0 0.00% 16:00 03/28 EDT
OPEN
9.13
PREV CLOSE
9.11
HIGH
9.46
LOW
9.12
VOLUME
943.29K
TURNOVER
0
52 WEEK HIGH
14.84
52 WEEK LOW
7.75
MARKET CAP
357.24M
P/E (TTM)
-5.7858
1D
5D
1M
3M
1Y
5Y
Pulmonx: Revisiting Thesis Following Management Change
Pulmonx Corporation's shares have performed poorly over the past year, returning -16%. The company's CEO recently announced his retirement, raising questions about potential changes in corporate strategy. Pulmonx is a medical device company developing a treatment for patients with severe emphysema. In my opinion, the market for endobronchial valves is much smaller than anticipated. I reduced my rating on PulmonX Corporation to a sell a year ago.
Seeking Alpha · 2d ago
Weekly Report: what happened at LUNG last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at LUNG last week (0311-0315)?
Weekly Report · 03/18 09:08
Weekly Report: what happened at LUNG last week (0304-0308)?
Weekly Report · 03/11 09:08
Weekly Report: what happened at LUNG last week (0226-0301)?
Weekly Report · 03/04 09:08
Pulmonx Announces Treatment Of The First Patient With The AeriSeal System In CONVERT II Pivotal Trial
AeriSeal System Shows Promise in Limiting Collateral Ventilation in severe COPD/Emphysema Patients to benefit from treatment with Zephyr Valves. The AeriSeal system is designed to block gaps in lung fissures and block collateral ventilation. The first patient in the CONVERT II Pivotal Trial is the first to be treated with the system. Pulmonx received approval to begin the CONvert II Trial in late 2023. The study is a multicenter, international study evaluating the safety and effectiveness of the Aeriseal System.
Benzinga · 02/26 13:02
Weekly Report: what happened at LUNG last week (0219-0223)?
Weekly Report · 02/26 09:09
Pulmonx Price Target Raised to $17.00/Share From $16.00 by Citigroup
Dow Jones · 02/23 17:09
More
About LUNG
Pulmonx Corporation is a commercial-stage medical technology company. The Company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), is designed to treat severe emphysema patients. The StratX Platform is a cloud-based quantitative CT analysis service that offers physicians with a report that is designed for its solution, which includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation and has been validated in multiple randomized controlled clinical trials.

Webull offers Pulmonx Corp stock information, including NASDAQ: LUNG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUNG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LUNG stock methods without spending real money on the virtual paper trading platform.